Co-Authors
This is a "connection" page, showing publications co-authored by PATRICK HWU and GREGORY A LIZEE.
Connection Strength
3.088
-
Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. 2021 07; 9(7).
Score: 0.196
-
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3K? Inhibition in PTEN Loss Melanoma. Clin Cancer Res. 2019 11 01; 25(21):6406-6416.
Score: 0.172
-
HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes. Nat Commun. 2017 09 06; 8(1):451.
Score: 0.151
-
Novel Treatments in Development for Melanoma. Cancer Treat Res. 2016; 167:371-416.
Score: 0.134
-
Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination. J Immunother. 2013 May; 36(4):276-86.
Score: 0.111
-
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
Score: 0.109
-
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res. 2013 Jan 15; 19(2):393-403.
Score: 0.108
-
Harnessing the power of the immune system to target cancer. Annu Rev Med. 2013; 64:71-90.
Score: 0.107
-
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
Score: 0.107
-
Antitumor T-cell responses contribute to the effects of dasatinib on c-KIT mutant murine mastocytoma and are potentiated by anti-OX40. Blood. 2012 Nov 29; 120(23):4533-43.
Score: 0.106
-
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-? inducible chemokines. Cancer Res. 2012 Oct 15; 72(20):5209-18.
Score: 0.106
-
Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma. Clin Cancer Res. 2012 Oct 01; 18(19):5329-40.
Score: 0.106
-
Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012 Apr; 35(3):276-82.
Score: 0.103
-
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res. 2012 Apr 15; 18(8):2326-35.
Score: 0.103
-
Detection and characterization of a novel subset of CD8?CD57? T cells in metastatic melanoma with an incompletely differentiated phenotype. Clin Cancer Res. 2012 May 01; 18(9):2465-77.
Score: 0.102
-
Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
Score: 0.096
-
Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin Cancer Res. 2010 Nov 15; 16(22):5458-68.
Score: 0.093
-
TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy. J Immunother. 2010 May; 33(4):371-81.
Score: 0.091
-
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest. 2008 Mar; 118(3):1165-75.
Score: 0.078
-
A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-cell clones. J Immunol Methods. 2008 Feb 29; 331(1-2):13-26.
Score: 0.076
-
IL-21 synergizes with IL-7 to augment expansion and anti-tumor function of cytotoxic T cells. Int Immunol. 2007 Oct; 19(10):1213-21.
Score: 0.076
-
Less yin, more yang: confronting the barriers to cancer immunotherapy. Clin Cancer Res. 2007 Sep 15; 13(18 Pt 1):5250-5.
Score: 0.075
-
Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res. 2006 Oct 01; 12(19):5801-8.
Score: 0.071
-
Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin Cancer Res. 2006 Aug 15; 12(16):4794-803.
Score: 0.070
-
Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res. 2006 Apr 01; 12(7 Pt 2):2359s-2365s.
Score: 0.068
-
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. Cancer Res. 2004 Sep 15; 64(18):6783-90.
Score: 0.061
-
Chromatin Remodelers Are Regulators of the Tumor Immune Microenvironment. Cancer Res. 2024 Apr 01; 84(7):965-976.
Score: 0.059
-
Correction: IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2024 Feb 01; 212(3):500.
Score: 0.059
-
The CX3CL1-CX3CR1 chemokine axis can contribute to tumor immune evasion and blockade with a novel CX3CR1 monoclonal antibody enhances response to anti-PD-1 immunotherapy. Front Immunol. 2023; 14:1237715.
Score: 0.057
-
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.
Score: 0.052
-
IL-1a Mediates Innate and Acquired Resistance to Immunotherapy in Melanoma. J Immunol. 2021 04 15; 206(8):1966-1975.
Score: 0.048
-
RNA editing derived epitopes function as cancer antigens to elicit immune responses. Nat Commun. 2018 09 25; 9(1):3919.
Score: 0.041
-
Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget. 2017 Nov 14; 8(57):96496-96505.
Score: 0.038
-
Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment. Melanoma Res. 2008 Aug; 18(4):241-5.
Score: 0.020
-
Survivin DNA vaccine generated specific antitumor effects in pancreatic carcinoma and lymphoma mouse models. Vaccine. 2007 Nov 14; 25(46):7955-61.
Score: 0.019
-
HLA-A0201 positive pancreatic cell lines: new findings and discrepancies. Cancer Immunol Immunother. 2007 May; 56(5):719-24.
Score: 0.018